Syngeneic tumor models are also used to investigate the antitumor activity of ICIs, including anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) [39] and anti-programmed death (PD)-1 anti-PD-L1 antibodies [31,40]. Here, CTLA4 is linked to neoplasm.